Want to see OTLC full AI Analyst Report?
Oncotelic Therapeutics (OTLC) AI Stock Analysis
Oncotelic Therapeutics
(Other OTC:OTLC)
The score is held down primarily by weak financial performance (minimal recurring revenue, persistent operating losses, and sustained cash burn with low earnings-to-cash conversion) and bearish technical trend signals (price below key moving averages with negative MACD). Valuation looks very low on P/E but is less persuasive given concerns that recent net income is not supported by core operations or cash flow, while corporate events are mixed with dilution risk from convertible financing.
Oncotelic Therapeutics (OTLC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $9.15M
- Dividend Yield
- ―
- Average Volume (3M)
- 337.12K
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- -0.03
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 41
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Oncotelic Therapeutics Business Overview & Revenue Model
Company Description
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound desig...
Oncotelic Therapeutics Financial Statement Overview
Summary
Financial performance is weak: revenue is minimal and inconsistent, operating losses persist, and operating/free cash flow remain deeply negative (ongoing cash burn). The unusually high TTM net income appears driven by non-operating or one-time items and does not align with operating trends or cash generation, reducing earnings quality. The balance sheet shows improved recent leverage, but historical volatility and swings in returns raise stability risk.
Income Statement
18Very NegativeBalance Sheet
45NeutralCash Flow
12Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 250.00K | 0 | 0 | 70.00K | 0 | 0 |
| Gross Profit | 250.00K | 0 | 0 | 70.00K | -12.84K | -61.51K |
| EBITDA | 360.34M | 361.46M | -3.80M | -6.86M | -5.60M | -9.06M |
| Net Income | 247.50M | 249.28M | -4.52B | -7.90M | 17.82M | -11.39M |
Balance Sheet | ||||||
| Total Assets | 394.75M | 393.09M | 26.68M | 30.01M | 36.12M | 23.61M |
| Cash, Cash Equivalents and Short-Term Investments | 186.01K | 88.86K | 86.13K | 170.41K | 241.45K | 568.77K |
| Total Debt | 13.89M | 13.91M | 13.09M | 12.57M | 11.26M | 8.99M |
| Total Liabilities | 131.31M | 131.36M | 19.20M | 18.40M | 16.92M | 15.45M |
| Stockholders Equity | 264.56M | 262.76M | 8.25M | 12.13M | 19.41M | 7.96M |
Cash Flow | ||||||
| Free Cash Flow | -1.52M | -1.38M | -740.27K | -1.32M | -1.45M | -4.43M |
| Operating Cash Flow | -1.52M | -1.38M | -740.27K | -1.32M | -1.45M | -4.43M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 1.62M | 1.39M | 656.00K | 1.25M | 1.13M | 4.53M |
Oncotelic Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLC, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 39.10 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OTLC.
Oncotelic Therapeutics Risk Analysis
Oncotelic Therapeutics disclosed 38 risk factors in its most recent earnings report. Oncotelic Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksOncotelic Therapeutics Peers Comparison
Overall Rating
GRCE48Neutral
CALC44Neutral
MAIA44Neutral- OTLC44Neutral
ELUT40Underperform
LTRN39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GRCE | 48Neutral | $40.81M | -1.54 | -35.78% | ― | ― | -43.60% |
| CALC | 44Neutral | $9.97M | -0.21 | 3398.40% | ― | ― | 15.37% |
| MAIA | 44Neutral | $67.92M | -1.74 | -211.15% | ― | ― | -7.28% |
| OTLC | 44Neutral | $7.48M | 0.03 | 123.80% | ― | ― | ― |
| ELUT | 40Underperform | $37.07M | 0.64 | 940.81% | ― | -48.76% | -3.02% |
| LTRN | 39Underperform | $9.87M | -0.41 | -456.35% | ― | ― | 9.68% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| OTLC | Oncotelic Therapeutics Inc | 0.02 | -0.09 | -84.76% | |
| GRCE | Grace Therapeutics, Inc. | 1.94 | -1.17 | -37.62% | |
| LTRN | Lantern Pharma, Inc. | 0.66 | -3.16 | -82.72% | |
| CALC | Calcimedica, Inc. | 1.46 | -13.49 | -90.23% | |
| ELUT | Elutia Inc. | 0.84 | -0.10 | -10.48% | |
| MAIA | MAIA Biotechnology, Inc. | 1.10 | -0.06 | -5.17% |
Oncotelic Therapeutics Corporate Events
Oncotelic showcases AI-driven oncology discovery framework
PositiveOn October 22, 2026, Oncotelic Therapeutics Chief Business Officer Saran Saund presented the company’s Partitioned Literature Aggregation framework at the 22nd Drug Discovery Strategic Summit in Millbrae, California. The talk detailed how parti...
Oncotelic highlights PDAOAI platform and BIO REBOOT initiative
PositiveOn October 7 and 8, 2026, Oncotelic Therapeutics representatives presented new technical details of their PDAOAI data-analytics platform and hepatocellular carcinoma research at the Drug Discovery 2026 conference in Burlingame, California. The platfo...
Oncotelic Announces New Convertible Note Financing Agreement
NegativeOn August 3, 2026, Oncotelic Therapeutics entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP, issuing a $178,410 convertible promissory note with a 12% original issue discount and 12% annual interest. The note can be conver...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026